AstraZeneca has halted a £200m expansion of its Cambridge research site, part of a £650m UK investment plan.
The project was expected to create 1,000 jobs, but follows the scrapping of a £450m facility in Merseyside.
A company spokesperson confirmed the pause, saying AstraZeneca continually reassesses its investment needs.
While UK plans stall, AstraZeneca pledged $50bn US investment by 2030, including new facilities in multiple states.
The pause caps a week of bad news for UK pharmaceuticals, including Merck cancelling a £1bn London research hub.
Industry leaders warn major companies may stop investing in Britain without stronger government support.
Sanofi and Eli Lilly also paused UK projects, citing an uncompetitive life sciences environment.
The sector disputes NHS drug pricing policies, pressing for a lower clawback rate to match other European markets.
AstraZeneca Pauses £200m Cambridge Expansion as UK Pharma Faces Setbacks
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
Add A Comment